Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2003Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy

Compared with aspirin 325 mg/day, 4 weeks of aspirin 81 mg/day resulted in significantly higher urinary d-TXB2 (p=0.04), while aspirin 1300 mg/day resulted in significantly lower urinary d-TXB2 (p<0.01).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does aspirin dosage affect serum and urinary markers of thromboxane synthesis in patients with vascular disease?

Population

48 patients with vascular disease, mean age 70 years

Comparison

Aspirin 81 mg/day or 1300 mg/day for 4 weeks vs Aspirin 325 mg/day for 4 weeks

Design

RCT, random assignment

Follow-up

12 weeks total (3 periods of 4 weeks)

Authors

RHRobert G. HartALAnne D. LeonardRTRobert L. Talbert

Discussion

Loading...

Member takes

Overview

Challenges low-dose aspirin preference for thromboxane suppression; confirms dose-dependent effects in vascular disease.

Structured PICO

Does aspirin dosage affect serum and urinary markers of thromboxane synthesis in patients with vascular disease?

P
Population
48 patients with vascular disease (52% clinical coronary artery disease, 29% cerebrovascular disease, 46% atrial fibrillation), mean age 70 years
I
Intervention
Aspirin 81 mg/day or 1300 mg/day for 4 weeks (following an initial 4-week run-in of aspirin 325 mg/day)
C
Comparator
Aspirin 325 mg/day for 4 weeks
O
Outcome
Levels of serum thromboxane B2 and urinary 11-dehydrothromboxane B2 (d-TXB2)surrogate

Different aspirin dosages significantly affect serum and urinary markers of thromboxane synthesis, demonstrating a dose-dependent suppression of thromboxane in patients with vascular disease.

Cite This Study

Hart et al. (2003) studied this question.

synapsesocial.com/papers/6a8fde5b41f68ebe50414352https://doi.org/10.1592/phco.23.5.579.32206
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High Risk of Cardiovascular Events in Patients, Biosynthesis of Aspirin-Resistant Thromboxane And The Risk Of Stroke, Myocardial Infarction Or Death2022
  2. 211-dehydrothromboxane B2 as a marker of acetylsalicylic acid resistance in patients with stable coronary artery disease2023
  3. 3Effects of different doses, enteric-coated preparation of aspirin, and sex on urinary 11-dehydrothromboxane B2 in healthy volunteers2010 · 6 citations
  4. 4Serial Urinary 11-Dehydrothromboxane B2, Aspirin Dose, and Vascular Events in Blacks After Recent Cerebral Infarction2004 · 29 citations
  5. 5Aspirin and Urinary 11-Dehydrothromboxane B <sub>2</sub> in African American Stroke Patients2002 · 27 citations